AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
SOUTH SAN FRANCISCO, Calif., Sept. 22, 2017 -- Catalyst Biosciences, Inc. (Nasdaq:CBIO) today announced that Nassim Usman, Ph.D., President and Chief Executive Officer, will present a corporate overview at the Ladenburg Thalmann 2017 Healthcare Conference being held in New York City. The Catalyst Biosciences presentation will be held on Tuesday, September 26, 2017 at 3:30 p.m. Eastern Time.
About Catalyst
Catalyst is a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications. Catalyst is focused on the field of hemostasis, including the subcutaneous prophylaxis of hemophilia and facilitating surgery in individuals with hemophilia. For more information, please visit www.catalystbiosciences.com.
Contacts: Investors: Fletcher Payne, CFO, Catalyst Biosciences 650.871.0761 [email protected] Media: Denise Powell 510.703.9491 [email protected]
